Revolutionary Breakthrough! Could Insight Corporation's Cancer Treatment Drug Change the Future: 15.2% for MSS Colorectal Cancer, 20–34% for Pancreatic Cancer

Incyte presented Phase 1 data for two drug candidates at ESMO 2025 (October 17-21, Berlin). The TGFBR2×PD-1 bispecific antibody INCA33890 showed an ORR of 15.2% in MSS colorectal cancer, including many previously treated cases, with safety generally within acceptable limits. A registration trial is planned to begin in 2026. The KRAS G12D inhibitor INCB161734 demonstrated an **ORR of 20–34% (dose-dependent)** and a high disease control rate in pancreatic cancer, prompting continued evaluation. On social media, under the hashtag #ESMO25, medical media and investors shared the news, with a mix of optimism and caution. Among investors, opinions were mixed, but there was notable appreciation for the "promise" shown in these challenging areas.